At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CMPS COMPASS Pathways plc
Post-Mkt 04-22 18:35:09 EDT
8.75
-0.50
-5.41%
盘后8.71
-0.04-0.46%
18:34 EDT
High9.35Low8.11Vol7.05M
Open9.31D1 Closing9.25Amplitude13.41%
Mkt Cap1.18BTradable Cap892.50MTotal Shares135.00M
T/O61.16MT/O Rate6.91%Tradable Shares102.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

EXPLAINER-What to know about psychedelic therapies cited by Trump
Reuters  ·  04-22 01:08
EXPLAINER-What to know about psychedelic therapies cited by Trump
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Whitehawk Therapeutics (WHWK), COMPASS Pathways (CMPS) and Monopar Therapeutics Inc (MNPR)
TIPRANKS  ·  04-21 19:00
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Whitehawk Therapeutics (WHWK), COMPASS Pathways (CMPS) and Monopar Therapeutics Inc (MNPR)
Compass Pathways enters collaboration with Osmind
TIPRANKS  ·  04-21 18:54
Compass Pathways enters collaboration with Osmind
Compass Pathways collaborates with Osmind to prepare clinics for psychedelic treatments
Reuters  ·  04-21 18:31
Compass Pathways collaborates with Osmind to prepare clinics for psychedelic treatments
Stock Track | COMPASS Pathways Soars 9.20% in Pre-market After Trump's Executive Order Supports Psychedelic Treatments
Stock Track  ·  04-21 16:08
Stock Track | COMPASS Pathways Soars 9.20% in Pre-market After Trump's Executive Order Supports Psychedelic Treatments
Stock Track | COMPASS Pathways Soars 9.51% in Overnight Trading After Trump's Executive Order Supports Psychedelic Treatments
Stock Track  ·  04-21 15:34
Stock Track | COMPASS Pathways Soars 9.51% in Overnight Trading After Trump's Executive Order Supports Psychedelic Treatments
Psychedelic Stocks Surge After Trump Supports Using Drugs Like LSD for Mental Health
Dow Jones  ·  04-21 09:54
Psychedelic Stocks Surge After Trump Supports Using Drugs Like LSD for Mental Health
NASD Most Active Issues
Dow Jones  ·  04-21 05:42
NASD Most Active Issues
Analysts Offer Insights on Healthcare Companies: COMPASS Pathways (CMPS) and Nuvalent (NUVL)
TIPRANKS  ·  04-21 02:40
Analysts Offer Insights on Healthcare Companies: COMPASS Pathways (CMPS) and Nuvalent (NUVL)
H.C. Wainwright Reaffirms Their Buy Rating on COMPASS Pathways (CMPS)
TIPRANKS  ·  04-21 01:35
H.C. Wainwright Reaffirms Their Buy Rating on COMPASS Pathways (CMPS)
BUZZ-U.S. STOCKS ON THE MOVE-Adobe, Agios, QXO
Reuters  ·  04-20 23:53
BUZZ-U.S. STOCKS ON THE MOVE-Adobe, Agios, QXO
Compass Pathways Price Target Maintained With a $14.00/Share by BTIG
Dow Jones  ·  04-20 23:10
Compass Pathways Price Target Maintained With a $14.00/Share by BTIG
Psychedelic Drug Stocks Surge with Compass Pathways up 37%; Atai Beckley up 28%. Trump Accelerates Psychedelic Research With $50 Million Ibogaine Commitment
Benzinga  ·  04-20 22:32
Psychedelic Drug Stocks Surge with Compass Pathways up 37%; Atai Beckley up 28%. Trump Accelerates Psychedelic Research With $50 Million Ibogaine Commitment
Definium Therapeutics Adds 15.3%, Compass Pathways Rises 40%, GH Research Gains 16.4%
THOMSON REUTERS  ·  04-20 21:32
Definium Therapeutics Adds 15.3%, Compass Pathways Rises 40%, GH Research Gains 16.4%
Enveric Biosciences up 150%, U.S.‑Listed Shares of Cybin Rise 2.7%
THOMSON REUTERS  ·  04-20 21:32
Enveric Biosciences up 150%, U.S.‑Listed Shares of Cybin Rise 2.7%
BUZZ-U.S. STOCKS ON THE MOVE-TopBuild, MDA Space, Biogen
Reuters  ·  04-20 21:05
BUZZ-U.S. STOCKS ON THE MOVE-TopBuild, MDA Space, Biogen
Top Premarket Gainers
MT Newswires Live  ·  04-20 19:53
Top Premarket Gainers
Psychedelic Pharmaceutical Companies' Shares Rise Following Executive Order
Dow Jones  ·  04-20 18:39
Psychedelic Pharmaceutical Companies' Shares Rise Following Executive Order
Psychedelic Drug Developers Rise Premarket After Trump Orders FDA to Expedite Reviews
THOMSON REUTERS  ·  04-20 18:37
Psychedelic Drug Developers Rise Premarket After Trump Orders FDA to Expedite Reviews
Definium Therapeutics up 14.5%, Compass Pathways up 21.5%, GH Research up 18.9%, Enveric Biosciences up 6.6%, U.S.‑Listed Shares of Cybin up 15.5%
THOMSON REUTERS  ·  04-20 18:37
Definium Therapeutics up 14.5%, Compass Pathways up 21.5%, GH Research up 18.9%, Enveric Biosciences up 6.6%, U.S.‑Listed Shares of Cybin up 15.5%

Introduction

Company Name.
COMPASS Pathways plc
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
Issue price:
--